NCT05786521View on ClinicalTrials.gov

Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

May 20, 2024

Study Completion Date

May 20, 2024

Conditions
AgingDiabetes Mellitus, Type 2PreDiabetesOverweight and Obesity
Interventions
DRUG

Semaglutide Injectable Product

Semaglutide will be started at 0.25mg once a week for 4 weeks followed by 0.5mg once weekly for 4 weeks followed by 1.0mg once a week for 12 weeks.

BEHAVIORAL

Lifestyle Counseling

Lifestyle Counseling will be provided throughout study intervention

Trial Locations (1)

78229

UT Health San Antonio, San Antonio

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

The University of Texas Health Science Center at San Antonio

OTHER